Jaguar Health, Inc.
Pharmaceutical Preparations · SAN FRANCISCO · CA
Moderate confidence (50%)
Updated Oct 13, 2026, 12:05 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Jaguar Health, Inc. received a delisting notice from its exchange (May 1, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Jaguar Health, Inc. received a delisting notice from its exchange
May 1, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 1, 2026, Jaguar Health, Inc. (the Company ) received a written notification (the Notice ) from the staff of the Listing Qualifications Department (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that, as a result of the 1-for-35 reverse stock split of the Company s issued and outstanding shares of common stock, par value $0.0001 per share (the Common Stock ) effected on April 30, 2026, the Company has a post reverse stock split number of publicly he…”
Jaguar Health, Inc. received a delisting notice from its exchange
Apr 24, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2026, Jaguar Health, Inc. (the Company ) received a decision letter from the Nasdaq Hearings Panel ( Panel ) granting the Company s request to continue its listing on The Nasdaq Stock Market LLC ( Nasdaq ), subject to the condition that, on or before May 15, 2026, the Company shall demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule ). This decision follows the Company s hearing before the Panel on April 7, 2026, regarding its non-compliance wit…”
Jaguar Health, Inc. received a delisting notice from its exchange
Mar 5, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 5, 2026, Jaguar Health, Inc. (the Company ) received a written notification (the Notice ) from the staff of the Listing Qualifications Department (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that because the bid price for the Company s common stock for the previous 30 consecutive business days had closed below the minimum $1.00 per share, the Company was no longer in compliance with the requirement for continued listing on Nasdaq under Nasdaq Listing Rul…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker JAGX on Nasdaq.
- SEC CIK
- 0001585608
- Website
- —
- —
- Headquarters
- SAN FRANCISCO, CA
- Also known as
- Jaguar Animal Health, Inc.
- Legal entities
- Jaguar Health, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
Jaguar Health, Inc. — Pharmaceutical Preparations (SIC 2834) — SAN FRANCISCO, CA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 1, 2026, Jaguar Health, Inc. (the Company ) received a written notification (the Notice ) from the staff of the Listing Qualifications Department (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that, as a result of the 1-for-35 reverse stock split of the Company s issued and outstanding shares of common stock, par value $0.0001 per share (the Common Stock ) effected on April 30, 2026, the Company has a post reverse stock split number of publicly he…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2026, Jaguar Health, Inc. (the Company ) received a decision letter from the Nasdaq Hearings Panel ( Panel ) granting the Company s request to continue its listing on The Nasdaq Stock Market LLC ( Nasdaq ), subject to the condition that, on or before May 15, 2026, the Company shall demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule ). This decision follows the Company s hearing before the Panel on April 7, 2026, regarding its non-compliance wit…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 5, 2026, Jaguar Health, Inc. (the Company ) received a written notification (the Notice ) from the staff of the Listing Qualifications Department (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that because the bid price for the Company s common stock for the previous 30 consecutive business days had closed below the minimum $1.00 per share, the Company was no longer in compliance with the requirement for continued listing on Nasdaq under Nasdaq Listing Rul…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:32 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:11 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:32 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:44 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.